{"schema_version":"secwatch.filing_event.v1","accession":"0001567264-25-000081","form_type":"8-K","ticker":"INTS","cik":"0001567264","company_name":"INTENSITY THERAPEUTICS, INC.","filed_at":"2025-08-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.379262+00:00","generated_at":"2026-05-17T14:30:34.653817+00:00","sec_items":["5.03","8.01","9.01"],"event_type":"regulatory","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Intensity Therapeutics reduces stockholder quorum to one-third, regains Nasdaq equity compliance after $6.6M raise","bullets":["Bylaws amended to require one-third voting power for quorum (down from majority).","Company raised ~$6.6M in July 2025 via ATM to address Nasdaq equity deficiency.","Nasdaq confirmed compliance with $2.5M stockholders' equity requirement as of June 30, 2025.","Nasdaq warned that non-compliance in next periodic report could trigger delisting.","Q2 10-Q filed Aug 7, 2025, supported the equity position."],"urls":{"canonical":"https://secwatch.observer/filing/0001567264-25-000081","json":"https://secwatch.observer/filing/0001567264-25-000081.json","markdown":"https://secwatch.observer/filing/0001567264-25-000081.md","text":"https://secwatch.observer/filing/0001567264-25-000081.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1567264/000156726425000081/0001567264-25-000081-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1567264/000156726425000081/intensity-20250808.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T14:30:34.653817+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"855b27415610568cc4a9c2b8989ca9b5b332a6dc","claim":"INTENSITY THERAPEUTICS, INC.: Amended Section 2.7 of Bylaws to reduce stockholder meeting quorum requirement from majority to at least one-third of voting power entitled to vote, effective August 12, 2025 (effective 2025-08-12).","evidence_excerpt":"On August 12, 2025, the Board of Directors of Intensity Therapeutics, Inc. (the “Company”), adopted an amendment (the “Amendment”) to the Amended and Restated Bylaws of the Company (the “Bylaws”). The changes to the Bylaws pursuant to the Amendment are effective as of August 12, 2025. The Amendment amends Section 2.7 of the Bylaws, dealing with a quorum at meetings of stockholders, to generally provide that a quorum is at least one-third of the voting power of the stock issued and outstanding and entitled to vote, present in person, or by remote communication, if applicable, or represented by proxy. Prior to effectiveness of the Amendment, a quorum is a majority of the voting power of the stock issued and outstanding and entitled to vote, present in person, or by remote communication, if applicable, or represented by proxy.","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1567264/000156726425000081/0001567264-25-000081-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"bylaw amendment"},{"label":"Effective","value":"2025-08-12"}],"fact_type":"governance_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}